- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00727896
"Information Technology Methodology for Patient Motivation in Diabetes Management."
"Reinforcement of Adherence to Prescription Recommendations in Diabetic Patients Using Short Message Service (SMS)- A Pilot Study"
Type 2 diabetes is a chronic metabolic disorder requiring lifestyle modification and medicines, adherence to which has to be practised on a daily basis.
Motivation of patients to adhere to treatment is difficult in clinical practice. It is well documented that majority of patients do not reach the glycaemic targets even in the centres of excellence. Regular short service messages (SMS) through cell phones could have a positive effect on behaviour and adherence to life style changes and compliance to drugs. It may be practical and feasible to use information technology as an effective and simple tool for motivating patients to adhere to the prescribed treatment regimen.
In diabetic patients, frequent reminders regarding the need for adherence to LSM and drugs by the medical professionals will improve the compliance.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In diabetic patients, frequent reminders by the medical professionals on the need for adherence to Life Style Modification (LSM) and drugs will improve the compliance. SMS may be an effective and cheap tool of communication. Improved compliance is likely to result in better glycaemic control.
Out of total number of 200, consecutive randomization of 100 patients each to SMS or usual care arms will be done. Patients in the SMS group will get SMS once in 3 days as a reminder. Patients will be reviewed at 3, 6, 9 and 12 months from the date of randomization
Fasting and 2hr postprandial glucose and HbA1c will be tested during each visit.
At baseline and at the end of the study, lipids, and renal function test will also be done. A validated questionnaire will be used to assess physical activity, diet habits, adherence to drug prescriptions and frequency of monitoring of blood glucose. . Body weight, blood pressure, biochemical variables, scores for diet and physical activity and compliance to drugs, will be compared using students 't' test or chi-square test as relevant.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Tamil nadu
-
Chennai, Tamil nadu, India, 600 008
- India Diabetes Research Foundation and Dr.A.Ramachandran's Diabetes Hospitals
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female, 30-65 yrs of age at the time of entry and have type 2 diabetes for a minimum period of 5 years.
- HbA1C ranging 8.0-10.0%
- Patients either receiving OHA and / or insulin
Exclusion Criteria:
- Type 1 diabetes
- Patients with history of blindness, decreased vision
- Serious vascular complications :
- Cancer
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1 is experimental with SMS
Arm 1 is experimental with SMS intervention
|
Earlier life style modification and existing drug therapy was used and now SMS is added as a tool for reminder
|
Active Comparator: 2 is (active comparator) standard care
Arm 2 is the usual care arm (standard care)
|
Life style modification and drug therapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Behavioural changes resulting in diet, better adherence to treatment.
Time Frame: At intervals of three months for one year
|
At intervals of three months for one year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Reduction in HbA1c, other glycemic measures and improvement in blood lipid parameters
Time Frame: Annual
|
Annual
|
Collaborators and Investigators
Investigators
- Principal Investigator: Samith A Shetty, M.B.B.S, MDRC, India Diabetes Research Foundation (IDRF) and Dr.A.Ramachandran's Diabetes Hospitals
Publications and helpful links
General Publications
- 1) Ramachandran A; Snehalatha C; Mary S; Mukesh B; Bhaskar AD; Vijay V. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 49: 289-297, 2006. 2) Murugesan N; Snehalatha C; Shobana R; Roglic G; Ramachandran A. Awareness about diabetes and its complications in the general and diabetic population in a city in Southern India. DRCP 77 : 433-7, 2007. 3) Ramachandran A; Shobana R; Snehalatha C; Augustine C; Murugesan N; Viswanathan V; Kapur A; Williams R. Increasing expenditure on health care incurred by diabetic subjects in a developing country: a study from India. Diabetes Care 30 : 252-6, 2007. 4)Ramachandran A, Mary S, Yamuna A, Murugesan N,Snehalatha C. High Prevalence of Diabetes and Cardiovascular Risk Factors Associated with urbanization in India. DOI:10.2337/dc07-1207
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SMS001IDRF
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes
-
Antonio Di MauroCompletedType-2 DiabetesItaly
-
DiaMedica Therapeutics IncCompletedDiabetes Type 2Netherlands
-
RenJi HospitalUnknownType 2 Diabetes.China
-
University of Erlangen-Nürnberg Medical SchoolCompletedType 2-diabetesGermany
-
Chengdu Brilliant Pharmaceutical Co., Ltd.Not yet recruitingType 2 Diabetes Mellitus
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingType 2 Diabetes MellitusChina
-
Xiangya Hospital of Central South UniversityRecruitingType 2 Diabetes MellitusChina
-
University of Alabama at BirminghamCompletedType 2 Diabetes MellitusUnited States
-
Imperial College LondonAstraZeneca; Huma; North West London Collaboration of CCGs (NWL CCGs); Imperial...CompletedType 2 Diabetes MellitusUnited Kingdom
-
Universiti Sains MalaysiaCompleted
Clinical Trials on Pre-coded messages
-
Henry Ford Health SystemCompletedOrthopedic DisorderUnited States
-
University of California, Los AngelesNational Institute of Allergy and Infectious Diseases (NIAID)Completed
-
University of PittsburghCompletedDiet, Sodium-Restricted | Heart Failure C14.280.434United States
-
Brigham and Women's HospitalPatient Safety Technologies, Inc.Completed
-
Centre for Global Health Research, TorontoTata Memorial Hospital; International Institute for Population Sciences; HM Patel...Unknown
-
University of ZurichCompleted
-
Stanford UniversityNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
Yonsei UniversityCompletedEar,Nose and Throat SurgeryKorea, Republic of
-
Hanoi University of Public HealthNational Institutes of Health (NIH); Fogarty International Center of the National... and other collaboratorsRecruitingSmoking | Smoking Cessation | Telemedicine | MindfulnessVietnam
-
Friedrich-Alexander-Universität Erlangen-NürnbergPhilipps University Marburg Medical CenterCompleted